Philippe Camus, M.D.

Dijon, France

Back

The Drug-Induced Respiratory Disease Website

Nivolumab

An anti–PD-1 monoclonal antibody formerly known as BMS-936558 (PMID 23714523). Approximate rate of pneumonitis is 3%, with 1% being severe (Grade 3/4). Incidence of pneumonitis is higher in those patients on concomitant nivolumab plus ipilimumab or other ICPI combo therapy (PMID 25891304)

II - Myocardial dysfunction - Heart failure

II.d

Cardiovascular collapse - Cardiogenic shock - Hypotension

III - Myocardial ischemia - Coronary artery disease

III.a

Coronary artery disease (acute) - Myocardial ischemia/infarction

IV - Heart block (bundle branch-, AV-block)

IV.a

Heart block (bundle branch- or AV-)

V - Myocarditis

V.a

Myocarditis (can be fulminate/fulminant)

VII - Cardiotoxicity

VII.a

‘Cardiotoxicity’

X - Pulmonary edema

X.a

Pulmonary edema, cardiogenic

XII - Pericardial involvement

XII.b

Pericardial effusion (w/wo tamponade)
XII.n

Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XXII - Acute respiratory/cardiorespiratory failure

XXII.b

Acute lung injury - ARDS

XXVIII - Large airway involvement

XXVIII.k

Rhinosinusitis

XXIX - Small airway involvement

XXIX.a

Bronchospasm - Wheezing - Asthma
XXIX.e

Obliterative bronchiolitis (an imaging and/or pathological pattern consistent with)
XXIX.i

Exacerbation or deterioration of preexisting COPD
XXIX.l

Bronchiolitis (a clinical-imaging pattern suggestive of)

XXXII - Esophageal pathology

XXXII.e

Esophageal toxicity
XXXII.j

Esophageal necrosis

XXXVI - Autoimmune syndromes - Systemic reactions or conditions

XXXVI.m

DRES syndrome - DRESS-like reaction - Drug hypersensitivity syndrome
XXXVI.q

Tumor lysis syndrome (TLS)